EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

The effect of the combined treatment with tnf and anti b16 melanoma monoclonal antibody mab on established single b16 liver tumor



The effect of the combined treatment with tnf and anti b16 melanoma monoclonal antibody mab on established single b16 liver tumor



Proceedings of the American Association for Cancer Research Annual Meeting 30: 393




(PDF emailed within 1 workday: $29.90)

Accession: 033785448

Download citation: RISBibTeXText



Related references

Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-a and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. Journal of Immunology 144: 63-71, 1990

The effect of anti bl6 melanoma monoclonal antibody on established murine b16 melanoma liver metastases. Proceedings of the American Association for Cancer Research Annual Meeting 28: 384, 1987

Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases. Cancer Research 47(11): 2771-2776, 1987

Induction of antibody-dependent cellular cytotoxicity in vivo by IFN-alpha and its antitumor efficacy against established B16 melanoma liver metastases when combined with specific anti-B16 monoclonal antibody. Journal of Immunology 144(11): 4463-4471, 1990

Treatment of established b16 melanoma lung metastases with lak cells and anti b16 melanoma monoclonal antibody. Proceedings of the American Association for Cancer Research Annual Meeting 29: 428, 1988

Effect of recombinant human tumor necrosis factor alpha on the induction of antibody-dependent cellular cytotoxicity in the treatment of established B16 melanoma liver nodules. Cancer Immunology, ImmunoTherapy 31(4): 243-249, 1990

Improved tumor targeting of rhenium-186-labeled anti-human high-m.w. melanoma-associated antigen monoclonal antibody 763.74 following purification with anti-idiotypic monoclonal antibody MK2-23. International Journal of Cancer 78(4): 486-490, 1998

Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases. Cancer Research 48(24 Pt 1): 7140-7145, 1988

A human monoclonal anti-melanoma single chain Fv antibody cloned from tumor-infiltrating B lymphocytes. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 483, 1995

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Research 68(23): 9884-9891, 2008

Synergistic in vitro and in vivo anti-tumor effect of daunomycin-anti-96-kDa melanoma-associated antigen monoclonal antibody CL 207 conjugate and recombinant IFN-gamma. Journal of Immunology 141(4): 1410-1417, 1988

Non tumor distribution of zme 018 anti melanoma monoclonal antibody compared to anti p 97 in melanoma patients. Journal of Nuclear Medicine 26(5): P112-P113, 1985

The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity. Plos One 9(9): E107875-E107875, 2015

Anti-CD40 monoclonal antibody treatment of B16 melanoma-bearing mice increases the number of CD8+ T cells in the tumor. Proceedings of the American Association for Cancer Research Annual Meeting 44: 554, July, 2003